Scancell founder says the company is ready to commercialise novel medicines to counteract cancer. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksTempleton Emerging Markets Regulatory News (TEM)

Share Price Information for Templeton Emerging Markets (TEM)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 157.40
Bid: 157.40
Ask: 158.00
Change: -0.20 (-0.13%)
Spread: 0.60 (0.381%)
Open: 157.60
High: 158.00
Low: 156.80
Prev. Close: 157.60
TEM Live PriceLast checked at -
Templeton Emerging Markets is an Investment Trust

To provide long-term capital appreciation for private and institutional investors seeking exposure to global emerging markets, supported by both strong customer service and corporate governance.

Find out More

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Edison reviews Templeton Emerging Markets (TEM)

30 Jan 2020 13:25

RNS Number : 4725B
Templeton Emerging Markets IT PLC
30 January 2020
 

 

London, UK, 30 January 2020

Edison reviews Templeton Emerging Markets Investment Trust (TEM)

Templeton Emerging Markets Investment Trust (TEMIT) has two experienced managers - Chetan Sehgal (based in Singapore) and Andrew Ness (based in Edinburgh). In 2019, they delivered a very strong year of performance in both absolute and relative terms, and are continuing to find attractive investment opportunities across a range of sectors and geographies. The managers are able to draw on a large and well-resourced investment team that has been refreshed in recent years, seeking quality companies that can be held for the long term. Ness says that TEMIT offers a portfolio with superior growth prospects, that is trading broadly in line with its benchmark, the MSCI Emerging Markets index.

 

TEMIT's shares are currently trading at a 10.1% discount to cum-income NAV, which compares with the 10.1% to 12.1% range of average discounts over the last one, three, five and 10 years. The trust historically paid a single annual dividend, but now pays out twice a year in July and January. TEMIT's FY19 dividend was 6.7% higher year-on-year, and it currently yields 1.9%.

Click here to view the full report.

 

Subscribe to Edison's content to receive reports by email.

All reports published by Edison are free-to-access and available on the website.

 

About Edison: Edison is an investment research and advisory company, with offices in North America, Europe, the Middle East and AsiaPac. The heart of Edison is our world-renowned equity research platform and deep multi-sector expertise. At Edison Investment Research, our research is widely read by international investors, advisers and stakeholders. Edison Advisors leverages our core research platform to provide differentiated services including investor relations and strategic consulting.

Edison is authorised and regulated by the Financial Conduct Authority.

Edison is not an adviser or broker-dealer and does not provide investment advice. Edison's reports are not solicitations to buy or sell any securities.

For more information please contact Edison:

Mel Jenner, +44 (0)20 3077 5720

Sarah Godfrey, +44 (0)20 3681 2519

investmenttrusts@edisongroup.com

 

Learn more at Edisongroup.com and connect with Edison on:

LinkedIn https://www.linkedin.com/company/edison-group- 

Twitter www.twitter.com/Edison_Inv_Res 

YouTube www.youtube.com/edisonitv 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
NRABXGDBXDXDGGG
Date   Source Headline
6th Apr 20234:56 pmRNSTransaction in Own Shares
6th Apr 20239:28 amRNSNet Asset Value(s)
5th Apr 20235:00 pmRNSTransaction in Own Shares
5th Apr 20239:46 amRNSNet Asset Value(s)
4th Apr 20235:04 pmRNSTransaction in Own Shares
4th Apr 20239:36 amRNSNet Asset Value(s)
3rd Apr 202310:01 amRNSNet Asset Value(s)
3rd Apr 20239:14 amRNSTotal Voting Rights
3rd Apr 20237:00 amRNSKepler Trust Intelligence: New Research
31st Mar 20239:37 amRNSNet Asset Value(s)
30th Mar 20235:19 pmRNSTransaction in Own Shares
30th Mar 20239:22 amRNSNet Asset Value(s)
29th Mar 20238:36 amRNSNet Asset Value(s)
28th Mar 20239:07 amRNSNet Asset Value(s)
27th Mar 20234:51 pmRNSTransaction in Own Shares
27th Mar 20238:53 amRNSNet Asset Value(s)
24th Mar 20238:44 amRNSNet Asset Value(s)
23rd Mar 20239:47 amRNSNet Asset Value(s)
22nd Mar 20238:40 amRNSNet Asset Value(s)
21st Mar 20239:10 amRNSNet Asset Value(s)
20th Mar 202310:00 amRNSPortfolio Update
20th Mar 20238:55 amRNSNet Asset Value(s)
17th Mar 20239:38 amRNSNet Asset Value(s)
16th Mar 20238:52 amRNSNet Asset Value(s)
15th Mar 20238:25 amRNSNet Asset Value(s)
14th Mar 20238:44 amRNSNet Asset Value(s)
13th Mar 20234:56 pmRNSTransaction in Own Shares
13th Mar 20238:49 amRNSNet Asset Value(s)
10th Mar 20233:57 pmRNSHolding(s) in Company
10th Mar 20238:57 amRNSNet Asset Value(s)
9th Mar 20239:14 amRNSNet Asset Value(s)
8th Mar 20234:58 pmRNSTransaction in Own Shares
8th Mar 20239:01 amRNSNet Asset Value(s)
7th Mar 20235:06 pmRNSTransaction in Own Shares
7th Mar 20239:10 amRNSNet Asset Value(s)
6th Mar 20234:55 pmRNSTransaction in Own Shares
6th Mar 20239:11 amRNSNet Asset Value(s)
3rd Mar 20235:04 pmRNSTransaction in Own Shares
3rd Mar 202310:09 amRNSNet Asset Value(s)
2nd Mar 20239:25 amRNSNet Asset Value(s)
1st Mar 20235:01 pmRNSTransaction in Own Shares
1st Mar 20239:44 amRNSNet Asset Value(s)
1st Mar 20239:19 amRNSTotal Voting Rights
28th Feb 20239:58 amRNSNet Asset Value(s)
27th Feb 202310:04 amRNSNet Asset Value(s)
27th Feb 20238:48 amRNSEdison issues update on Templeton Emerging Markets
24th Feb 20235:09 pmRNSTransaction in Own Shares
24th Feb 20239:28 amRNSNet Asset Value(s)
23rd Feb 20238:51 amRNSNet Asset Value(s)
22nd Feb 20239:27 amRNSNet Asset Value(s)

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.